Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;38(4):390-402.
doi: 10.2337/cd19-0100.

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance

Jaime P Almandoz  1 , Ildiko Lingvay  1 , Javier Morales  2 , Carlos Campos  3
Affiliations

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance

Jaime P Almandoz et al. Clin Diabetes. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Kaplan-Meier analysis of persistence among patients switching from a previous GLP-1 receptor agonist to dulaglutide once weekly, exenatide twice daily or once weekly, or liraglutide once daily. Patients were switched from dulaglutide (5.0%), exenatide twice daily (28.1%), exenatide once weekly (17.4%), or liraglutide (49.5%). Data are from a retrospective analysis of a German prescription database using data from 1 February 2014 to 31 March 2017. Reprinted with permission from Otto et al. (57). BID, twice daily; QW, once weekly.
FIGURE 2
FIGURE 2
Practical algorithm for switching between once-daily and once-weekly GLP-1 receptor agonist therapies. *First dose of 7 or 14 mg to be administered 1–7 days after last injection (based on limited advice in the prescribing information, which specifies only when switching from semaglutide 0.5 mg subcutaneous). †Assessment of equivalent dose is entirely based on authors’ opinion, which in turn is based on head-to-head clinical trials when available and/or clinical experience. Other reasons for switching could include patient preference, concern about drug interactions, and cost/insurance issues. Exenatide once weekly is not available at a lower dose but could be tried if this is an insurance-preferred GLP-1 receptor agonist. BID, twice daily; GLP-1RA, GLP-1 receptor agonist; QD, once daily; QW, once weekly.
See this image and copyright information in PMC

References

    1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–1705 - PubMed
    1. Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 2016;18:203–216 - PMC - PubMed
    1. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol Metab 2013;24:85–91 - PMC - PubMed
    1. Davies MJ, D’Alessio DA, Fradkin J, et al. . Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41:2669–2701 - PMC - PubMed
    1. Buse JB, Wexler DJ, Tsapas A, et al. . 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487–493 - PMC - PubMed

LinkOut - more resources